Lung transplantation in interstitial lung disease

Area of Science:

• Pulmonology
• Transplant Surgery
• Immunology

Background:

• Interstitial lung diseases (ILDs) like pulmonary fibrosis and sarcoidosis significantly impact lung function, often leading to end-stage disease.
• Lung transplantation is an established therapeutic option for select patients with end-stage ILDs.
• Limited donor availability from cadavers poses a challenge to transplantation accessibility.

Purpose of the Study:

• To discuss lung transplantation as a therapeutic option for end-stage interstitial lung disease.
• To review the success rates and challenges associated with lung transplantation for pulmonary fibrosis.
• To explore the potential of living-related donor lung transplantation and its application in sarcoidosis.

Main Methods:

• Review of current literature on lung transplantation outcomes for interstitial lung diseases.
• Analysis of donor pool limitations and strategies to expand donor availability.
• Discussion of patient selection criteria for lung transplantation.
• Examination of case studies involving living-related donor lung transplantation and sarcoidosis recurrence.

Main Results:

• Single lung transplantation for pulmonary fibrosis demonstrates good survival rates.
• Living-related donor lung transplantation has been successfully performed, potentially increasing donor availability.
• Lung transplantation is feasible for sarcoidosis patients, though allograft recurrence is noted.

Conclusions:

• Lung transplantation is a successful therapeutic modality for end-stage interstitial lung disease, particularly pulmonary fibrosis.
• Living-related donors offer a promising avenue to overcome donor pool limitations.
• While transplantation is possible for sarcoidosis, the long-term implications of allograft recurrence require further investigation.